Xencor, MD Anderson enter collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of cancer pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
MD Anderson and Xencor enter strategic collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of patients with cancer
This collaboration joins Xencor’s innovative XmAb
® technology and protein engineering expertise to create bispecific antibodies with MD Anderson’s expertise in the research and discovery of novel therapeutic antibodies, including the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, part of MD Anderson’s Therapeutics Discovery division.
“Xencor’s modular antibody engineering platform enables the rapid generation of XmAb
® bispecific antibodies, and our research collaboration with MD Anderson will further expand the use of our technology to explore novel therapeutic targets, which could result in the creation of new therapies for patients with cancer,” said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.